Cargando…

Efficacy of Imatinib Mesylate Neoadjuvant Treatment for a Locally Advanced Rectal Gastrointestinal Stromal Tumor

Surgery is the standard treatment for a primary gastrointestinal stromal tumor (GIST); however, surgical resection is often not curative, particularly for large GISTs. In the past decade, with imatinib mesylate (IM), management strategies for GISTs have evolved significantly, and now IM is the stand...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoon, Kyu Jong, Kim, Nam Kyu, Lee, Kang Young, Min, Byung Soh, Hur, Hyuk, Kang, Jeonghyun, Lee, Sarah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Coloproctology 2011
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3145886/ https://www.ncbi.nlm.nih.gov/pubmed/21829770 http://dx.doi.org/10.3393/jksc.2011.27.3.147

Ejemplares similares

Impact of neoadjuvant treatment on rectal gastrointestinal stromal tumors
por: Cheong, Chinock, et al.
Publicado: (2022)

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
por: Din, Omar S, et al.
Publicado: (2008)

Optimal timing of surgery after neoadjuvant chemoradiation therapy in locally advanced rectal cancer
por: Jeong, Duck Hyoun, et al.
Publicado: (2013)

ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor
por: Rink, Lori, et al.
Publicado: (2013)

Concurrent Male Gynecomastia and Testicular Hydrocele after Imatinib Mesylate Treatment of a Gastrointestinal Stromal Tumor
por: Kim, Hawk, et al.
Publicado: (2005)

Circumferential Resection Margin Involvement in Stage III Rectal Cancer Patients Treated with Curative Resection Followed by Chemoradiotherapy: A Surrogate Marker for Local Recurrence?
por: Kang, Jeonghyun, et al.
Publicado: (2013)

Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours
por: Gauden, Ruth, et al.
Publicado: (2011)

Complete pathological response to Imatinib mesylate in an extraintestinal gastrointestinal stromal tumor
por: Quezada, Nicolás, et al.
Publicado: (2014)

Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
por: Tang, Sumin, et al.
Publicado: (2017)

Oncologic Impact of Fewer Than 12 Lymph Nodes in Patients Who Underwent Neoadjuvant Chemoradiation Followed by Total Mesorectal Excision for Locally Advanced Rectal Cancer
por: Kim, Woo Ram, et al.
Publicado: (2015)

The Impact of Postoperative Complications on Long-term Oncologic Outcomes After Laparoscopic Low Anterior Resection for Rectal Cancer
por: Park, Eun Jung, et al.
Publicado: (2016)

Different clinical features according to the anastomotic leakage subtypes after rectal cancer surgeries: contained vs. free leakages
por: Park, Eun Jung, et al.
Publicado: (2018)

Imatinib-induced hepatitis treated by corticosteroids in a patient with metastatic gastrointestinal stromal tumor
por: Kang, Min Kyu, et al.
Publicado: (2019)

Initial application of transanal endoscopic microsurgery for high-risk lower rectal gastrointestinal stromal tumor after imatinib mesylate neoadjuvant chemotherapy: A case report
por: Liu, Qiaofei, et al.
Publicado: (2017)

Imatinib Mesylate: Past Successes and Future Challenges in the Treatment of Gastrointestinal Stromal Tumors
por: Ksienski, Doran
Publicado: (2011)

The Merendino procedure following preoperative imatinib mesylate for locally advanced gastrointestinal stromal tumor of the esophagogastric junction
por: Staiger, Wilko I, et al.
Publicado: (2008)

Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach
por: Kurokawa, Yukinori, et al.
Publicado: (2017)

Neoadjuvant versus adjuvant imatinib in primary localized gastrointestinal stromal tumor
por: Ling, Jiayu, et al.
Publicado: (2023)

Cost-Effectiveness of Robotic Surgery for Rectal Cancer Focusing on Short-Term Outcomes: A Propensity Score-Matching Analysis
por: Kim, Chang Woo, et al.
Publicado: (2015)

Recurrent Gastrointestinal Stromal Tumors in the Imatinib Mesylate Era: Treatment Strategies for an Incurable Disease
por: Platoff, Rebecca M., et al.
Publicado: (2017)

Primary Prostatic Extra-Gastrointestinal Stromal Tumor Treated with Imatinib Mesylate as Neoadjuvant and Adjuvant Therapy: A Case Report and Literature Review
por: Shen, Haixiang, et al.
Publicado: (2019)

Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: Case report
por: Hughes, Brett, et al.
Publicado: (2004)

Gynecomastia during imatinib mesylate treatment for gastrointestinal stromal tumor: a rare adverse event
por: Liu, HeLi, et al.
Publicado: (2011)

Imatinib mesylate treatment in a dog with gastrointestinal stromal tumors with a c-kit mutation
por: IRIE, Mitsuhiro, et al.
Publicado: (2015)

Establishment of a GIST-T1 gastrointestinal stromal tumour cell line resistant to imatinib mesylate
por: Zhou, Yongjian, et al.
Publicado: (2018)

Recent Advancements in the Treatment of Rectal Gastrointestinal Stromal Tumor: In Era of Imatinib
por: Qu, Hui, et al.
Publicado: (2022)

Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate
por: Wu, Ting-Jung, et al.
Publicado: (2006)

Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate
por: Rausch, Jessica L., et al.
Publicado: (2016)

Imatinib Mesylate for Patients With Unresectable or Recurrent Gastrointestinal Stromal Tumors: 10-Year Experience From Vietnam
por: Hung, Kien Do, et al.
Publicado: (2019)

Imatinib Mesylate-Induced Hyperpigmentation of the Nose and Palate
por: Song, Hyo Sang, et al.
Publicado: (2014)

Efficacy and safety of neoadjuvant imatinib therapy for patients with locally advanced rectal gastrointestinal stromal tumors: A multi-center cohort study
por: Li, Weihao, et al.
Publicado: (2022)

Clinicopathologic change of gastrointestinal stromal tumor after neoadjuvant imatinib followed by surgical resection
por: Kang, Gil Ho, et al.
Publicado: (2012)

Downstaging of a Rectal Gastrointestinal Stromal Tumor by Neoadjuvant Imatinib Therapy Allowing for a Conservative Surgical Approach
por: dos Santos Fernandes, Gustavo, et al.
Publicado: (2009)

Prospective Evaluation of Neoadjuvant Imatinib Use in Locally Advanced Gastrointestinal Stromal Tumors: Emphasis on the Optimal Duration of Neoadjuvant Imatinib Use, Safety, and Oncological Outcome
por: Wang, Shang-Yu, et al.
Publicado: (2019)

Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate
por: Sawaki, Akira, et al.
Publicado: (2009)

Tuberculous and Non-Tuberculous Granulomatous Lymphadenitis in Patients Receiving Imatinib Mesylate (Glivec) for Metastatic Gastrointestinal Stromal Tumor
por: Agaimy, Abbas, et al.
Publicado: (2013)

The impact of early adjuvant chemotherapy in rectal cancer
por: Noh, Gyoung Tae, et al.
Publicado: (2020)

Lichenoid Drug Eruption after Low-Dose Imatinib Mesylate Treatment
por: Lee, Jae-Hyung, et al.
Publicado: (2013)

Management of Skin Toxicity Related to the Use of Imatinib Mesylate (STI571, Glivec™) for Advanced Stage Gastrointestinal Stromal Tumours
por: Scott, Lucy C., et al.
Publicado: (2005)

Prolonged Therapy with Imatinib Mesylate before Surgery for Advanced Gastrointestinal Stromal Tumor Results of a Phase II Trial
por: Doyon, C., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_hn4f6r2go227eg72tkpqd2kllq